Charles River Laboratories International, Inc. (CRL) Income Statement

The revenue trajectory shows a clear deceleration from the post-pandemic boom, with growth oscillating between -3.2% and +1.2% over the past two years. This stagnation appears to be driven by reduced client demand rather than pricing pressure, as the company's gross margin has actually improved in recent quarters. The lack of organic growth suggests CRL is relying on market share gains to offset sector headwinds, a strategy that may face limits if the funding environment remains subdued.

The gross margin improvement suggests better capacity utilization or cost controls in the DSA segment, yet the operating margin has not fully recovered, implying that SG&A expenses are absorbing some of the gains. The negative net margin of -3.59% in the latest quarter, despite positive operating income, points to significant non-operating charges, likely impairments or restructuring costs, which may continue to weigh on profitability. Investors should monitor whether the gross margin expansion is sustainable or merely a temporary effect of cost-cutting.

The stability of operating income at approximately $120M across 2026Q1 and Q2, despite a slight revenue increase, suggests that variable costs are rising in tandem with revenue, preventing operating leverage from materializing. The company's heavy investment in facilities and personnel means that any revenue decline directly pressures margins, as seen in the 2025Q1 operating margin of 7.6%. This lack of scalability is a structural challenge that may require a shift toward higher-margin services to improve profitability.

The sharp rise in SG&A in 2026Q2, despite flat revenue, suggests either one-time costs or a lack of disciplined expense control. This volatility makes it difficult to predict future operating margins, as the company appears to be adjusting its cost base in response to demand fluctuations. The reported EPS beat in 2026Q2 may have been aided by lower COGS, but the SG&A spike could signal that the beat is not sustainable without continued revenue growth.

The 2025Q4 charge appears to be a strategic reset, possibly related to portfolio restructuring or goodwill impairment, which has allowed the company to report higher operating margins in 2026. However, the continued net losses in 2026Q1 and Q2 suggest that the impairment was not a one-time event, and additional charges may be forthcoming. This inflection highlights the risks of CRL's aggressive M&A strategy, which may have overpaid for assets during the peak of the market, and the lasting impact on shareholder value.